StockWatch
·

Zydus Lifesciences Ltd Q2 FY27 Results

ZYDUSLIFEQ2 FY27 Results
Filing
Result:Weak· Market: Down#Margin squeeze

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue7.9K1.3%29.2%
Total Income8.0K1.0%29.0%
Expenditure6.8K0.1%50.9%
PBT1.2K5.5%26.9%
Net Profit927.706.3%25.1%
OPM23.97%0.13pp8.39pp
NPM11.54%0.65pp8.33pp
EPS9.280.8%25.8%
View full financials

Revenue growth of 29% is largely inorganic (acquisition-driven), while adjusted PAT fell ~28% YoY on margin compression (OPM 32.4%→24.0%, NPM 19.9%→11.5%) from acquisition-related finance costs and amortization, missing even the lowest street estimate.

ZYDUS LIFESCIENCES · Q2 FY27 · THE VERDICT

Revenue surges 29%, profit sinks 25%—the Saro investment revealed

Zydus nailed revenue growth and EBITDA margin guidance, yet net profit collapsed 25% year-over-year. The call shows why: Saro commercialization (₹115–120 Cr per quarter), R&D inflation (~₹650 Cr quarterly), and acquisition depreciation are compressing PAT despite a headline 24% margin hold.

07 Nov 2026 · 6 min read
Revenue

₹7909.6 Cr

+29.2% YoY

Net Profit

₹927.7 Cr

-25.1% YoY

EBITDA margin

24%

on guidance

Branded revenue share

57%

+150 bps

Zydus hit its headline targets—revenue +29%, EBITDA margin 24%—yet profit tanked 25% year-over-year. That paradox is the quarter. Management guided on margin percentages while allowing material cost inflation to hollow out the bottom line, a sleight that the street caught immediately under questioning. The culprit is plain: Saroglitazar (Saro) commercialization burning ₹115–120 crore per quarter, R&D spend inflated to ~₹650 crore quarterly (8–8.5% of revenue), and acquisition-related depreciation spiking across the P&L. Headline margin holds; organic profit doesn't.

Where the profit went

The margin bridge is the story. Saro alone consumed ₹115–120 crore in Q2—not yet generating revenue (commercial launch targeted March FY28), but burning cash upfront. Management guided ₹100 million (~₹400+ crore annually at current burn) ongoing. R&D spending, mapped at ~₹650 crore per quarter (up from historical norms), reflects an innovation-intensive phase: 30 vanilla generic filings, 10–12 complex/biologics/vaccines in-flight, 4 clinical trials ongoing. This is deliberate but expensive. Add acquisition-related depreciation and amortization (Assertio, Cadilia, Cadent, Amplitude Surgical all in integration), and the P&L pressure is structural, not cyclical. The 24% EBITDA margin claim, while technically delivered, masks the deterioration in cash generation at the net profit line.

Q2 FY27 Margin Drivers, ₹ Cr
0242.67485.3372824EBITDA margin maintained200Depreciation spike (M&A)650R&D inflation115Saro burn
EBITDA margin holds at reported 24%, but cost inflation below erodes PAT. Saro Q2 spend (₹115–120 Cr), R&D (~₹650 Cr), and acquisition depreciation are material headwinds.

Management's claims graded

What holds up
  • Strong double-digit growth across all businesses

  • India branded +19% YoY, outperforming IPM (10–11%) by 200–400 bps

  • EBITDA margin 24% maintained despite Saro ramp

  • Saro commercialization on track for March FY28 launch

  • 15–20 ANDAs, 505(b)(2)s expected next 2–3 quarters

What changed on this call

Saro timeline shifted. November was the original target; now March FY28. A quarter-plus delay pushes meaningful revenue contribution to FY29–FY30, extending the investment phase. FY28 guidance deferred. Management said nothing on FY28 revenue, PAT, or EBITDA targets—typically a caution flag. Branded mix upgraded. Branded formulations now 57% of revenue, up 150 basis points, tracking toward the medium-term 2/3 goal. This is deliberate strategy: higher-margin branded over generics. R&D spending embedded. ~₹650 crore per quarter is now the new baseline, not a temporary spike. No moderation expected. Acquisition accretion vague. Rolvedon (Assertio add-on) promised profitable day-one; Cadilia and Amplitude Surgical positioned as long-term bets. ROI timelines unquantified.

Looking for a March launch and obviously we would still see hiring of sales field force and other things continuing the front-end teams. Commercial expense around $100 million annually.

How the street is positioned

The stock closed at ₹1,197.9, holding above its 20-day, 50-day, and 200-day simple moving averages—a bullish setup. It sits 9.54% below its all-time high of ₹1,324.3, but 43% above its 52-week low of ₹835.5, a strong recovery arc that suggests institutional conviction in the long-term story. The RSI reads 56.4 (neutral zone), neither overbought nor oversold. Foreign institutional investors hold a steady 6.88% (down marginally from 6.95% prior quarter), while domestic institutions ticked up 7 basis points to 11.27%. Promoter stake remains at 75.01%, stable and unchanged. No bulk or block trades evident. The ownership mix signals neither panic nor aggressive accumulation, but the stock's placement above all key moving averages and its recovery from the 52-week trough suggests the market has already priced in the near-term Saro investment phase and is betting on long-term upside. That confidence sits on Keyruda biosimilar approval, the 15–20 pipeline launches, and Saro's March entry.

The bull-bear ledger

Why the bull case holds
  • Revenue +29% is broad-based: India branded +19%, intl +33%, NA +21%, consumer wellness +76%

  • Branded business mix improving to 57%; medium-term 2/3 target credible and higher-margin

  • India branded outperforming market by 200–400 bps; market share gains sustained

  • Saro Phase III PBC data positive; $30B+ market, 20% share aspiration by FY30+

  • Keyruda biosimilar BLA filed with USFDA; first-to-file on $20B Keytruda market

  • 15–20 generic and 505(b)(2) approvals expected next 2–3 quarters; pipeline velocity high

  • Net debt/EBITDA 0.62x; deleveraging underway, leverage manageable

Why the bear case warns
  • PAT collapsed 25% YoY despite 29% revenue growth; margin compression structural

  • Saro investment ₹115–120 Cr per quarter; Q2 spend already front-loaded, H2 ramp likely

  • No FY28 revenue, PAT, or EBITDA guidance stated; management deferred clarity

  • Keyruda faces patent litigation (Keytruda IP); appeals court decision timing uncertain

  • Mirabegron erosion ongoing; base US business steady but exposed if acceleration falters

  • R&D spend embedded at ~₹650 Cr/quarter; no moderation expected, caps near-term margins

  • Acquisition integration costs unquantified; Cadilia, Assertio, Cadent accretion timeline vague

Ranked risks

Key concerns, ordered by how much they should weigh on a holder

Saro launch delay or regulatory re-query

High

March FY28 target already slipped from November. Further delays push meaningful revenue to FY29+, extending investment phase. ₹115–120 Cr quarterly burn continues without offset.

PAT margin compression unaddressed

High

Management led on EBITDA % maintenance but avoided PAT decline upfront. Analysts had to push for answers. Signals discomfort with profitability trajectory.

Keyruda biosimilar IP litigation outcome

High

Appeals court decision on Keytruda patent determines US launch timing. Delayed approval extends FY28–FY29 headwind. Binary outcome; no middle ground.

Mirabegron erosion accelerates

Medium

NA base business currently steady, but Mirabegron market share declining. Palbociclib generic launch Sept–Oct FY27 offers offset; if insufficient, US base revenue at risk.

Acquisition integration costs overrun

Medium

Assertio, Cadilia, Cadent, Amplitude all in integration. Depreciation spiked ₹200+ Cr; ROI and accretion timelines not quantified. If profitability delayed beyond FY28, leverage rises.

R&D spending inflation unsustainable

Medium

~₹650 Cr/quarter (8–8.5% of revenue) is new baseline. No moderation expected. If generic approvals stall or Saro launch delays, R&D becomes a pure cost center for longer.

What to watch next

Three things that resolve the debate
  • 1 · Saro March FY28 launch execution

    Any slip or FDA query re-emergence is a red flag. Hit the March date and begin field hiring/commercial buildout on schedule, and the long-term case strengthens. Miss it, and the investment trough extends.

  • 2 · 15–20 generic/505(b)(2) approvals in next 2–3 quarters

    Pipeline velocity is a near-term PAT offset. Every Q3–Q4 FY27 approval that lands validates management's R&D spend and gives baseline revenue traction independent of Saro.

  • 3 · FY28 guidance + Keyruda biosimilar approval status

    Management must commit to FY28 revenue, PAT, or EBITDA targets next quarter, and signal Keyruda BLA review progress. Silence on either is a sell signal; clarity restores credibility.

Zydus is executing a high-conviction franchise strategy: India branded consolidation, Saro late-stage asset acquisition, biosimilar entry via Keyruda, and acquisition-driven specialty scale. But the near-term cost is real. Revenue +29% is solid; profit -25% is a warning. The stock's position above key moving averages and FII steadiness suggest patience for the Saro payoff, but that patience has a duration—18–24 months into FY28–FY29 before profitability re-accelerates. Until then, the number to watch is not headline margin (24% EBITDA holds on management claims), but organic PAT growth and Q&A candor on why the gap between revenue and profit is widening, not narrowing. A Hold rating holds until Saro generates revenue or FY28 guidance clarifies the profit roadmap.

Informational and educational content only. Not investment advice.